Evidence map›Paper›PMID 39719705›Full record

ArticleMolecular cell2025

3D chromatin hubs as regulatory units of identity and survival in human acute leukemia.

Giovanni Gambi, Francesco Boccalatte, Javier Rodriguez Hernaez, Ziyan Lin, Bettina Nadorp, Alexander Polyzos, Jimin Tan, Kleopatra Avrampou, Giorgio Inghirami, Alex Kentsis and 3 more

Abstract read
In one paragraph

Article in Molecular cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential.Computational and structural biotechnology journal · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giovanni GambiDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA; Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA.
Francesco BoccalatteDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA; Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy. Electronic address: francesco.boccalatte@nyulangone.org.
Javier Rodriguez HernaezDivision of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA; Applied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, NY, USA.
Ziyan LinDivision of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA; Applied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, NY, USA.
Bettina NadorpDivision of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA; Applied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, NY, USA.
Alexander PolyzosSanford I. Weill Department of Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Jimin TanDivision of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA; Applied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, NY, USA.
Kleopatra AvrampouDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA; Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA.
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Alex KentsisMolecular Pharmacology Program, Sloan Kettering Institute and Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Departments of Pediatrics, Pharmacology, Physiology & Biophysics, Weill Cornell Medical College, Cornell University, New York, NY, USA.
Effie ApostolouSanford I. Weill Department of Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Iannis AifantisDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA; Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: ioannis.aifantis@nyulangone.org.
Aristotelis TsirigosDivision of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA; Applied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: aristotelis.tsirigos@nyulangone.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael Jason de la Cruz · 1985 to 2026
$347.4M
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Nancy Chan · 1985 to 2026
$83.1M
The impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 2019 to 2026
$17.0M
Drug Resistant Pathways in Relapsed Acute Lymphoblastic Leukemia(ALL)R01CA140729 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L. · 2010 to 2020
$4.8M
Targeting Epigenetic Heterogeneity in Pediatric T cell leukemia: Epi-Clones as Drivers of ChemoresistanceR01CA252239 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aristotelis Tsirigos · 2021 to 2026
$3.7M
Dissecting innate immune signaling in pre-leukemia evolutionR01CA271455 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Iannis Aifantis, Daniel Starczynowski · 2022 to 2026
$3.2M
mRNA stability and its impact on hematopoiesis and acute leukemiaR01CA266212 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis · 2022 to 2026
$2.7M
Mechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5M
Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcomeR01CA260028 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LIONNET, TIMOTHEE · 2021 to 2025
$2.2M
Mapping and targeting 3D regulatory elements in leukemia and lymphoma-SupplementR01CA298153 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis, Aristotelis Tsirigos · 2025 to 2026
$1.9M
NCI NIH HHS P01 CA229086NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA140729NCI NIH HHS R01 CA228135NCI NIH HHS R01 CA252239NCI NIH HHS R01 CA260028NCI NIH HHS R01 CA266212NCI NIH HHS R01 CA271455NCI NIH HHS R01 CA298153
6 · The paper itself

Abstract

Cancer progression involves genetic and epigenetic changes that disrupt chromatin 3D organization, affecting enhancer-promoter interactions and promoting growth. Here, we provide an integrative approach, combining chromatin conformation, accessibility, and transcription analysis, validated by in silico and CRISPR-interference screens, to identify relevant 3D topologies in pediatric T cell leukemia (T-ALL and ETP-ALL). We characterize 3D hubs as regulatory centers for oncogenes and disease markers, linking them to biological processes like cell division, inflammation, and stress response. Single-cell mapping reveals heterogeneous gene activation in discrete epigenetic clones, aiding in patient stratification for relapse risk after chemotherapy. Finally, we identify MYB as a 3D hub regulator in leukemia cells and show that the targeting of key regulators leads to hub dissolution, thereby providing a novel and effective anti-leukemic strategy. Overall, our work demonstrates the relevance of studying oncogenic 3D hubs to better understand cancer biology and tumor heterogeneity and to propose novel therapeutic strategies.

Indexed as

ChromatinEpigenesis, GeneticCell Line, TumorGene Expression Regulation, LeukemicHumansOncogenesPrecursor T-Cell Lymphoblastic Leukemia-LymphomaSingle-Cell AnalysisChromatinchromatin structureheterogeneityHiChIPhubsleukemiamodulesMYBscATAC

Identifiers

PMID39719705
PMCPMC11934262

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.